

3rd Annual International Erdheim-Chester Disease Medical Symposium

The University of Texas MD Anderson Cancer Center

Faculty Center | 3rd Floor, Rooms 1,2,7,8 | 1400 Pressler St. | Houston, TX 77030

October 8th, 2015

Time	Activity	Presenter
7:00 – 8:00 am	Registration and Breakfast	
8:00 - 8:15 am	Opening/Welcome/Introduction	Filip Janku, MD PhD MD Anderson Cancer Center
8:15 – 9:00 am	<i>Keynote presentation:</i> Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms	Omar Abdel-Wahab, MD, PhD MSKCC
9:00 – 10:15 am 4 selected oral presentations (15 mins + 3 minutes discussion) Chair: TBD	Tocilizumab for ECD	Lorenzo Dagna, MD Marina Ferrarini, MD Vita-Salute San Raffaele University
	Infliximab in ECD	Julien Haroche, MD, PhD Hospitalier Pitié-Salpêtrière
	BRAF inhibitors in ECD ad overlap histiocytoses, an update 2015	Julien Haroche, MD, PhD Zahir Amoura, MD Hospitalier Pitié-Salpêtrière
	Targeted Delivery of Hemoglobin-Cladribine Conjugate Inhibits Proliferation of Cells Originating from Human Histiocytic Lymphomas	Irina Eberle-Ayres Stephen Cutler, PhD David Bell, MSc, PhD TheraPure Biopharma, Inc.
10:15 - 10:25am	Break	
10:25 – 12:00 am 5 selected oral presentations (15 mins + 3 minutes discussion) Chair: TBD	Analysis of the neuro-radiological phenotypes, objective CNS responses to treatment and the long-term neuro-radiological evolution of the ECD	Roei Mazor, MD Sheba Medical Center
	Does the absence of classic histology exclude ECD?	Thomas Colby, MD Mayo Clinic, Arizona
	Low –frequency KRAS mutations in patients with BRAF-mutated ECD	Filip Janku, MD PhD MD Anderson Cancer Center
	CLIA laboratory testing of urinary BRAF V600E DNA mutations: application in the management of patients with histiocytic disease	Adrianna Muniz, PhD Mark Erlander, PhD Trovogene, Inc.
	Accepting Illness When Loss of Function is Permanent: A Model of Functional Adaptation	Susan Robertson, PhD NIH

Time	Activity	Presenter
12:00 – 1:00 pm	Lunch	
1:00 – 2:00 pm 3 selected oral presentations (15 mins + 3 minutes discussion) Chair: TBD	Oral manifestation of ECD	Juvanee Estrada-Veras, MD Pamela Gardner, DMD NIH
	Cardiac health in ECD	Juvanee Estrada-Veras, MD William Gahl, MD, PhD NIH
	Diffuse reduction of cerebral grey matter volumes in ECD	Eli Diamond, MD MSKCC
2:00 – 3:00 pm	<i>Panel discussion:</i> Clinical Trials in ECD <i>Moderator:</i> Eli Diamond, MD MSKCC	Filip Janku, MD, PhD, MD Anderson Juvanee I. Estrada-Veras, MD, NIH Augusto Vaglio, MD, PhD, University of Parma Lorenzo Dagna, Vita-Salute San Raffaele University
3:00 – 3:10 pm	Break	
3:10 – 4:10 pm	<i>Panel discussion:</i> Establishing Patients' Registries and Retrospective Multi-center Outcome Analyses <i>Moderator:</i> Achille Aouba, MD Caen, France	Achille Aouba, MD, Chu Caen Juvanee I. Estrada-Veras, MD, NIH Julien Haroche, MD, PhD, Hospitalier Pitié-Salpêtrière Jean-Francois Emile, MD, PhD, Versailles University Kathleen Brewer, ECD Global Alliance
4:10 – 4:40 pm	<i>Keynote presentation:</i> Social Media in the Rare Disease World	Timothy Craig Allen, M.D., J.D. University of Texas Medical Branch
4:40 – 4:45pm	Symposium Conclusion, Next Year's Symposium Host, 2017 Hosting Candidate Vote Group Ideas and Projects, Closing Remarks	Filip Janku, MD, PhD, MD Anderson Kathleen Brewer, ECD Global Alliance